Relevance of high-dose chemotherapy in solid tumours.

Abstract:

:Drug resistance is a major problem in the treatment of solid tumours. Based on a steep dose-response relationship for especially alkylating agents on tumour cell survival, high-dose chemotherapy was considered of interest for the treatment of solid tumours. Results of phase 1 and 2 studies with high-dose chemotherapy in a variety of tumour types showed good response rates. Nowadays, several phase 3 studies are available especially in metastatic and high-risk breast cancer patients. The high expectations of high-dose chemotherapy did not come true. This review analyses results of randomised studies and comments on the discrepancy between findings in patients versus those in tissue culture. Potential factors involved are the presence of tumour stem cells with different characteristics from more mature tumour cells, limitations in drug escalation in the clinic, transplant mortality, trial design and tumour cell contamination of the haematopoietic stem cell transplant. Maturation of the results from recent studies indicating a more modest benefit in, e.g., adjuvant breast cancer balanced versus long-term side effects will ultimately determine the role of high-dose chemotherapy in certain solid tumours. In case of well-defined indications for high-dose chemotherapy, further selection of patients based on patient and tumour characteristics as well as the introduction of new agents will most likely play a role.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Nieboer P,de Vries EG,Mulder NH,van der Graaf WT

doi

10.1016/j.ctrv.2005.02.002

keywords:

subject

Has Abstract

pub_date

2005-05-01 00:00:00

pages

210-25

issue

3

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(05)00030-7

journal_volume

31

pub_type

杂志文章,评审
  • The role of bone markers in metastatic bone disease.

    abstract::Patients with advanced cancer often develop bone metastases that lead to significant skeletal morbidity and substantially reduced functionality and autonomy [Coleman RE, Rubens RD. Bone metastases. In: Clinical Oncology, 2nd edn. New York: Churchill Livingstone. 2004, p. 1091-128]. As current methods of diagnosing bon...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(06)80001-0

    authors: Coleman RE

    更新日期:2006-01-01 00:00:00

  • In vivo antitumor activity of ilmofosine.

    abstract::Ilmofosine is a cytostatic/cytotoxic thioether phospholipid derivative. The in vivo anti-tumour activity of this compound was investigated in a methylcholanthrene (MethA)-induced fibrosarcoma and in the 3Lewis-lung carcinoma systems, respectively. Ilmofosine showed antineoplastic and antimetastatic properties at oral ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(90)90055-k

    authors: Herrmann DB,Pahlke W,Opitz HG,Bicker U

    更新日期:1990-09-01 00:00:00

  • Arsenical-based cancer drugs.

    abstract::Arsenic is a semi-metal or metalloid with two biologically important oxidation states, As(III) and As(V). As(III), in particular, reacts with closely spaced protein thiols, forming stable cyclic dithioarsinite complexes in which both sulfur atoms are bound to arsenic. It is this reaction that is mostly responsible for...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.05.001

    authors: Dilda PJ,Hogg PJ

    更新日期:2007-10-01 00:00:00

  • Management of a novel immune deficiency with IL-2 therapy.

    abstract::The present study describes a female child, who had a primary defect in the ability of her T-cells to secrete interleukin-2. Numbers of B- and T-cells were normal, but their functions were severely deficient. The patient had decreased immunoglobulins and poor ability to mount antibody responses. Phytohemagglutinin (PH...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(89)90034-0

    authors: Pahwa R,Paradise C,Good RA

    更新日期:1989-06-01 00:00:00

  • The emerging role of MET/HGF inhibitors in oncology.

    abstract::The N-methyl-N'-nitroso-guanidine human osteosarcoma transforming gene (MET) receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) control cellular signaling cascades that direct cell growth, proliferation, survival, and motility. Aberrant MET/HGF activation has been observed in many tumor types, can ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2013.02.001

    authors: Scagliotti GV,Novello S,von Pawel J

    更新日期:2013-11-01 00:00:00

  • Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis.

    abstract:PURPOSE:Neoadjuvant chemotherapy followed by surgery (NACT + S) has been compared with definitive chemoradiothherapy (CRT) in randomized clinical trials (RCTs) in stage IB2, IIA and IIB cervical cancer (1994 Figo stage). Our aim was to evaluate efficacy and toxicity of NACT + S and CRT and identify differences in clini...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.ctrv.2019.101945

    authors: Marchetti C,Fagotti A,Tombolini V,Scambia G,De Felice F

    更新日期:2020-02-01 00:00:00

  • Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review.

    abstract::Prostate cancer is the most common cancer in men. Overall survival is considered the best endpoint for clinical trials, but it is difficult to use in phase-2 studies. Although the reduction of PSA after cytotoxic chemotherapy has been identified as a valid surrogate for overall survival, it has not proven reliable for...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.03.008

    authors: Colloca G

    更新日期:2012-12-01 00:00:00

  • To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review.

    abstract:BACKGROUND:The association between alcohol intake and breast cancer recurrence or development of second primary breast cancer in the survivor population is unclear. The aim of this systematic review was to evaluate the existing evidence to assess the extent to which alcohol consumption is associated with breast cancer ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.09.010

    authors: Simapivapan P,Boltong A,Hodge A

    更新日期:2016-11-01 00:00:00

  • Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics.

    abstract::Cancer cells exhibit deregulation in multiple cellular signaling pathways. Therefore, treatments using specific agents that target only one pathway usually fail in cancer therapy. The combination treatments using chemotherapeutic agents with distinct molecular mechanisms are considered more promising for higher effica...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.07.001

    authors: Sarkar FH,Li Y

    更新日期:2009-11-01 00:00:00

  • Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials.

    abstract::At diagnosis, 25-40% of patients with small cell lung cancer (SCLC) are 70 years of age or older, and many of them have been undertreated because of fear of excessive toxicity associated with chemotherapy. Papers retrieved by a Medline search using the key words "elderly or older" and "small cell lung cancer" and by a...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2003.12.006

    authors: Sekine I,Yamamoto N,Kunitoh H,Ohe Y,Tamura T,Kodama T,Saijo N

    更新日期:2004-06-01 00:00:00

  • Rectal and colon cancer: Not just a different anatomic site.

    abstract::Due to differences in anatomy, primary rectal and colon cancer require different staging procedures, different neo-adjuvant treatment and different surgical approaches. For example, neoadjuvant radiotherapy or chemoradiotherapy is administered solely for rectal cancer. Neoadjuvant therapy and total mesorectal excision...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.06.007

    authors: Tamas K,Walenkamp AM,de Vries EG,van Vugt MA,Beets-Tan RG,van Etten B,de Groot DJ,Hospers GA

    更新日期:2015-09-01 00:00:00

  • Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?

    abstract::Hepatocellular carcinoma (HCC) is one of the most frequent and deadliest cancers worldwide. Liver transplantation, surgical resection or local ablation offer the best survival advantages but most patients either present when the tumor is in an advanced stage or the degree of underlying liver disease precludes these op...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.05.002

    authors: Meza-Junco J,Montano-Loza AJ,Liu DM,Sawyer MB,Bain VG,Ma M,Owen R

    更新日期:2012-02-01 00:00:00

  • Cancer stem cells niche: a target for novel cancer therapeutics.

    abstract::Nowadays, cancer has been a frequent disease, and the first or second most common cause of death worldwide. Despite a better understanding of the biology of cancer cells, the therapy of most cancers has not significantly changed for the past four decades. It is because conventional chemotherapies and/or radiation ther...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.10.004

    authors: Yi SY,Hao YB,Nan KJ,Fan TL

    更新日期:2013-05-01 00:00:00

  • The potential of melanoma antigen expression in cancer therapy.

    abstract::A potential new therapy for cancer is active specific immunotherapy with melanoma antigen (MAGE) gene products. The MAGE gene family comprizes a series of 12 closely related genes, some of which have been shown to be expressed in a variety of tumours of different histological origin. Peptides encoded by the MAGE genes...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.1999.0126

    authors: Gillespie AM,Coleman RE

    更新日期:1999-08-01 00:00:00

  • Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.

    abstract::Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with relatively poor prognosis, earlier disease recurrence and higher number of visceral metastases. Despite an increasing understanding of the molecular heterogeneity of TNBC, clinical trials of targeted agents have thus far...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.09.004

    authors: Schettini F,Giuliano M,De Placido S,Arpino G

    更新日期:2016-11-01 00:00:00

  • PARP inhibitors in ovarian cancer.

    abstract::Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways,...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.12.002

    authors: Franzese E,Centonze S,Diana A,Carlino F,Guerrera LP,Di Napoli M,De Vita F,Pignata S,Ciardiello F,Orditura M

    更新日期:2019-02-01 00:00:00

  • Pancreatic cancer: current and future treatment strategies.

    abstract::Pancreatic cancer is a disease with a high mortality rate and short survival, as a result of the high incidence of metastatic disease at diagnosis, the fulminant clinical course and the lack of successful therapeutic strategies. The administration of chemotherapeutic agents for the treatment of advanced disease has fa...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.02.005

    authors: Pliarchopoulou K,Pectasides D

    更新日期:2009-08-01 00:00:00

  • Unraveling galectin-1 as a novel therapeutic target for cancer.

    abstract::Galectins belong to a family of carbohydrate-binding proteins with an affinity for β-galactosides. Galectin-1 is differentially expressed by various normal and pathologic tissues and displays a wide range of biological activities. In oncology, galectin-1 plays a pivotal role in tumor growth and in the multistep proces...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2013.07.007

    authors: Astorgues-Xerri L,Riveiro ME,Tijeras-Raballand A,Serova M,Neuzillet C,Albert S,Raymond E,Faivre S

    更新日期:2014-03-01 00:00:00

  • Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?

    abstract::Despite improvements in the management of patients with early breast cancer, the prognosis for women with locally advanced breast cancer (LABC) remains poor. The potential goals of neoadjuvant treatment for this disease include down-sizing tumours to allow breast conservation as well as the possibility of improving su...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2004.09.008

    authors: Freedman OC,Verma S,Clemons MJ

    更新日期:2005-02-01 00:00:00

  • Inhibition of Hedgehog signaling in the gastrointestinal tract: targeting the cancer microenvironment.

    abstract::This review summarizes emerging information regarding the Hedgehog (Hh) signaling pathway during neoplastic transformation in the gastrointestinal tract. Although there is a role for the well-established canonical pathway in which Hedgehog ligands interact with their receptor Patched, there is sufficient evidence that...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2013.08.003

    authors: Merchant JL,Saqui-Salces M

    更新日期:2014-02-01 00:00:00

  • Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.

    abstract::Six major randomized clinical trials evaluating the role of taxanes in the adjuvant setting of breast cancer have demonstrated significant improvements in terms of efficacy in favour of the taxane treatment arm. In all cases, different anthracycline-based regimens were used as the control arm. Nevertheless, many clini...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.04.006

    authors: Estévez LG,Muñoz M,Alvarez I,Fernández Y,García-Mata J,Ruiz-Borrego M,Tusquets I,Seguí MA,Rodríguez-Lescure A,Adrover E,Lluch A

    更新日期:2007-08-01 00:00:00

  • Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.

    abstract::Since its first regulatory approval more than 10 years ago, oncologists have gained wide experience in using the oral fluoropyrimidine, capecitabine, as monotherapy or in combination with other agents and the body of evidence supporting these approaches continues to grow. Alongside this increasing experience has been ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.06.003

    authors: Barrett-Lee P,Bidard FC,Pierga JY

    更新日期:2009-11-01 00:00:00

  • A literature review of the association between diffusion-weighted MRI derived apparent diffusion coefficient and tumour aggressiveness in pelvic cancer.

    abstract::Diffusion-weighted magnetic resonance imaging (DW-MRI) is used extensively to improve tumour detection and localization because it offers excellent soft tissue contrast between malignant and non-malignant tissues. It also provides a quantitative biomarker; the apparent diffusion coefficient (ADC) can be derived from D...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.03.010

    authors: Bollineni VR,Kramer G,Liu Y,Melidis C,deSouza NM

    更新日期:2015-06-01 00:00:00

  • RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

    abstract::Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene express...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.08.004

    authors: Barata P,Sood AK,Hong DS

    更新日期:2016-11-01 00:00:00

  • Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.

    abstract::The chemo-immunotherapy (CIT) and chemo-adoptive immunotherapy (CAIT) regimens tested in the past decade are summarized. From them we have learned a great deal about the interactions between various chemotherapeutic agents, immune modulating agents and effector cells. The most commonly reported result in multi-modalit...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.2001.0222

    authors: Gomez GG,Hutchison RB,Kruse CA

    更新日期:2001-12-01 00:00:00

  • Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.

    abstract::Pancreatic cancer retains a poor prognosis among the gastrointestinal cancers and remains a challenge in oncology. In 1997, gemcitabine became the standard of care in metastatic setting. In the last decades, despite a number of clinical trials assessing novel cytotoxic agents and cell signaling inhibitors, overall sur...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.10.002

    authors: El Maalouf G,Le Tourneau C,Batty GN,Faivre S,Raymond E

    更新日期:2009-04-01 00:00:00

  • Beyond BRCA: new hereditary breast cancer susceptibility genes.

    abstract::Approximately 5-10% of breast cancer cases might be inheritable, up to 30% of which are due to BRCA1/2 mutations. During the past few years and thanks to technology evolution, we have been witnesses of an intensive search of additional genes with similar characteristics, under the premise that successful gene discover...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.10.008

    authors: Economopoulou P,Dimitriadis G,Psyrri A

    更新日期:2015-01-01 00:00:00

  • Physical exercise interventions in haematological cancer patients, feasible to conduct but effectiveness to be established: a systematic literature review.

    abstract:PURPOSE:To summarize and define the methodological quality of primary research findings obtained in exercise interventions, aimed at improving physical function or psychological well-being in patients treated for haematological malignancies. METHODS:Relevant trials were identified through a computerized Mesh-search in...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.09.008

    authors: Liu RD,Chinapaw MJ,Huijgens PC,van Mechelen W

    更新日期:2009-04-01 00:00:00

  • Improving attribution of adverse events in oncology clinical trials.

    abstract::Attribution of adverse events (AEs) is critical to oncology drug development and the regulatory process. However, processes for determining the causality of AEs are often sub-optimal, unreliable, and inefficient. Thus, we conducted a toxicity-attribution workshop in Silver Springs MD to develop guidance for improving ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2019.04.004

    authors: George GC,Barata PC,Campbell A,Chen A,Cortes JE,Hyman DM,Jones L,Karagiannis T,Klaar S,Le-Rademacher JG,LoRusso P,Mandrekar SJ,Merino DM,Minasian LM,Mitchell SA,Montez S,O'Connor DJ,Pettit S,Silk E,Sloan JA,Stewar

    更新日期:2019-06-01 00:00:00

  • Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.

    abstract::Antiangiogenic agents (AAs) have reported grater efficacy compared to interferon. Despite these advances, radiological complete response to therapy is rare. We meta-analyzed the incidence of complete response in patients treated with AAs and in controls in main randomized clinical trials for first-line therapy in meta...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2013.09.003

    authors: Iacovelli R,Alesini D,Palazzo A,Trenta P,Santoni M,De Marchis L,Cascinu S,Naso G,Cortesi E

    更新日期:2014-03-01 00:00:00